Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Cuts off a tumour's blood supply. | Sight-saving eye injection for wet macular degeneration. |
| Body system | Cancer | Eyes |
| Drug class | Targeted antibodies | Anti-VEGF injections |
| Supply | Prescription only | Prescription only |
| Main uses | Bowel cancer, Lung cancer, Ovarian and cervical cancer, Glioblastoma, Wet macular degeneration (off-label eye injections) | Wet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion |
| How it works | Stops tumours growing the blood vessels they need. | Blocks the signal that grows leaky vessels at the back of the eye. |
| Starts working | — | — |
| Half-life | About 20 days | — |
| Typical adult dose | 5–15 mg/kg IV every 2–3 weeks depending on cancer. | 2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further). |
| Forms | IV infusion, Intravitreal injection (ophthalmic forms in some countries) | Intravitreal injection |
| Common side effects | High blood pressure, Protein in urine, Nosebleeds, Tiredness | Eye redness, Floaters, Eye pain |
| Serious side effects | Bowel perforation, Bleeding, Poor wound healing, Clots | Eye infection (endophthalmitis), Retinal detachment, Raised eye pressure |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Usually avoidedContraception for 6 months after. | Usually avoidedNot recommended. |
| Breastfeeding | — | — |
| In use since | 2004 | 2011 |
| Brand names | United States: Avastin, Mvasi, ZirabevUnited Kingdom: Avastin, AlymsysIndia: Bevatas, Abevmy | United States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: Eylea |
| Legal status | — | — |
| ATC code | L01FG01 | S01LA05 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker